MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo
March 12 2018 - 7:00PM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number:4875), today announced that MediciNova
will participate in a panel session at the BIO Asia International
Conference in Tokyo, Japan on March 19, 2018. Yuichi Iwaki,
MD, PhD, President and Chief Executive Officer, will speak on the
panel, which will discuss partnerships and business development
strategies including licensing agreements and alternative deal
types.
Panel session details are as follows:
Date and Time: Monday, March 19, 2018 at 12:30 - 1:25
pm
Session: Globalizing Your Business Development
Strategy
Location: Grand Hyatt Tokyo, 6-10-3 Roppongi, Minato-Ku,
Tokyo, Japan, 106-0032
About the BIO Asia International Conference
The BIO Asia International Conference, co-hosted by the Japan
Bioindustry Association (JBA), brings together the global
biotechnology and pharmaceutical industry to explore licensing and
research collaborations in the current Asia-Pacific business and
policy environments. BIO brings more than ten years of experience
and expertise in biotech and pharmaceutical partnering to the
Asia-Pacific region, after successfully establishing the largest
partnering-focused events in the U.S. and Europe. Dr. Yuichi
Iwaki is a member of the BIO Asia advisory committee.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company
founded on acquiring and developing novel, small-molecule
therapeutics for the treatment of diseases with high unmet medical
needs with a primary commercial focus on the U.S. market.
MediciNova's current strategy is to focus on MN-166 (ibudilast) for
neurological disorders such as progressive MS, ALS and substance
dependence (e.g., methamphetamine dependence, opioid dependence,
alcohol dependence) and MN-001 (tipelukast) for fibrotic diseases
such as nonalcoholic steatohepatitis (NASH) and idiopathic
pulmonary fibrosis (IPF). MediciNova’s pipeline also includes
MN-221 (bedoradrine) for the treatment of acute exacerbations of
asthma and MN-029 (denibulin) for solid tumor cancers.
MediciNova is engaged in strategic partnering and other potential
funding discussions to support further development of its programs.
For more information on MediciNova, Inc., please visit
www.medicinova.com.
Statements in this press release that are not historical in
nature constitute forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements regarding the future development and
efficacy of MN-166, MN-001, MN-221 and MN-029. These
forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-001, MN-221 and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2017 and its subsequent periodic reports on
Forms 10-Q and 8-K. Undue reliance should not be placed on these
forward-looking statements, which speak only as of the date hereof.
MediciNova disclaims any intent or obligation to revise or update
these forward-looking statements.
INVESTOR CONTACT: Geoff O'BrienVice PresidentMediciNova,
Inc.info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2023 to Sep 2024